Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study
ConclusionsCT-P43 demonstrated equivalent efficacy to originator ustekinumab in patients with moderate to severe plaque psoriasis, with comparable pharmacokinetic, safety and immunogenicity profiles.Clinical Trial RegistrationClinicalTrials.gov Identifier: NCT04673786; date of registration: 17 December, 2020
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
More News: Clinical Trials | Drugs & Pharmacology | European Medicines Agency (EMA) | Psoriasis | Stelara | Study